Incidental splenic masses found during abdominal CT scan are rarely malignant, may not need follow-up.
Follow-up of incidental splenic masses noted during abdominal CT may not be indicated, according to a study published in the journal Radiology.
Researchers from Beth Israel Deaconess Medical Center in Boston, Mass., performed a retrospective study to evaluate whether an incidentally noted splenic mass at abdominal CT require further imaging work-up.
The researchers reviewed images, follow-up examinations, and electronic medical records of 379 patients with splenic masses detected during abdominal CT examinations; 214 (56.5 percent) were women and 165 (43.5 percent) men, mean age of 59.3 years. The patients were divided into three groups:
• Group 1: 145 (38.3 percent) patients with a history of malignancy
• Group 2: 29 (7.6 percent) patients with symptoms such as weight loss, fever, or pain related to the left upper quadrant and epigastrium
• Group 3: 205 (54.1 percent) patients with incidental findings
The final diagnoses of the causes of the masses were confirmed with imaging follow-up (83.9 percent), clinical follow-up (13.7 percent), and pathologic examination (2.4 percent).
The results showed the incidence of malignant splenic masses was 49 of 145 (33.8 percent) in the malignancy group, eight of 29 (27.6 percent) in the symptomatic group, and two of 205 (1 percent) in the incidental group. The incidental group consisted of new diagnoses of lymphoma in one (50 percent) patient and metastases from ovarian carcinoma in one (50 percent) patient. Malignant splenic masses in the incidental group were not indeterminate, because synchronous tumors in other organs were diagnostic of malignancy.
The researchers concluded that with an incidental splenic mass, the likelihood of malignancy is very low (1 percent) and follow-up of incidental splenic masses may not be indicated.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.